Utolsó frissítés :
08/05/2024
Infostab
Listák
Összesítő lista
Kompatibilitások keresése
Y-site kompatibilitási táblázat
Irodalom
Kutatócsoportok
Valistab
Poszter
Kapcsolatok
Támogatók
Szerző
Felhasználói útmutató
Hírlevél
Hydrochlorothiazide
Kémiai szerkezet
Irodalom : Hydrochlorothiazide
Type
Publikáció
2435
Napló
Allen LV, Jr, Erickson MA,
Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids
Am J Health-Syst Pharm 1996 ; 53: 2304-2309.
3361
Napló
Santovena A, Hernandez-Paiz Z, Farina J.B.
Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide.
Int J Pharm 2012 ; 423: 360-364.
3399
Poszter
Li Y.Y, Postma D.J, Wagenaar H.W.G.
Development of a hydrochlorothiazide 0.5 mg/mL oral solution for children.
EAHP Congress Paris 2013
3910
Napló
Polonini H.C, Silva S .L, de Almeida T.R, Brand?o M.A, Ferreira A.O.
Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions.
EJHP 2016 ; 23: 352-358.
4177
Napló
Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A.
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4.
Int J Pharm Compound 2018 ;22,6:516-526
4198
Napló
Uriel M, Gomez-Rincon C, Marro D.
Stability of regularly prescribed oral liquids formulated with SyrSpend® SF.
Pharmazie 2018 73;196-201
4256
Napló
Binson G, Beuzit K, Migeot V, Marco L, Troussier B, Venisse N, Dupuis A.
Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients.
Pharmaceutics 2019 ;11,190:
Mentions Légales
